<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is a controversial clinical entity that in its initial state is usually characterized by <z:e sem="disease" ids="C1273070" disease_type="Disease or Syndrome" abbrv="">left ventricular diastolic dysfunction</z:e> in patients with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> that cannot be explained by <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, or any other known <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It was reported in up to 52-60% of well-controlled type-II diabetic subjects, but more recent studies, using standardized tissue Doppler criteria and more strict patient selection, revealed a much lower prevalence </plain></SENT>
<SENT sid="2" pm="."><plain>The pathological substrate is myocardial damage, <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo>, interstitial <z:mp ids='MP_0003045'>fibrosis</z:mp>, structural and functional changes of the small coronary vessels, metabolic disturbance, and autonomic cardiac <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo> causes <z:hpo ids='HP_0001700'>myocardial necrosis</z:hpo> and <z:mp ids='MP_0003045'>fibrosis</z:mp>, as well as the increase of myocardial free radicals and oxidants, which decrease nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> levels, worsen the endothelial function, and induce myocardial <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> with <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> and decreased insulin sensitivity may also contribute to the <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical manifestations of diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> may include <z:hpo ids='HP_0002094'>dyspnea</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, atypical <z:hpo ids='HP_0100749'>chest pain</z:hpo>, and dizziness </plain></SENT>
<SENT sid="6" pm="."><plain>Currently, there is no specific treatment of diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> that targets its pathophysiological substrate, but various therapeutic options are discussed that include improving diabetic control with both diet and drugs (<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>), the use of <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi>, beta blockers, and <z:chebi fb="0" ids="38215">calcium channel blockers</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Daily physical activity and a reduction in body mass index may improve <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis by reducing the <z:chebi fb="105" ids="17234">glucose</z:chebi>/insulin ratio and the increase of both insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> oxidation by the skeletal and cardiac muscles </plain></SENT>
</text></document>